The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS)

References

• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7:34–51.
   PubMed Web of Science ®Google Scholar
• Boonpiyathad T, Sozener ZC, Satitsuksanoa P, et al. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333.
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47:161–175.
   PubMed Web of Science ®Google Scholar
• Matthes S, Stadler J, Barton J, et al. Asthma features in severe COPD: identifying treatable traits. Respir Med. 2018;145:89–94.
   PubMed Web of Science ®Google Scholar
• Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373:1241–1249.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–735.
   PubMed Web of Science ®Google Scholar
• Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Schivo M, Chan A, et al. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo). 2011;2011:861926.
   PubMedGoogle Scholar
• Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013;6:197–219.
   PubMed Web of Science ®Google Scholar
• Kiljander T, Helin T, Venho K, et al. Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15047.
   PubMed Web of Science ®Google Scholar
• GINA. Global initiative for asthma https://ginasthma.org/. [cited 2019 September 23]. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf
   Google Scholar
• GOLD. Global initiative for chronic obstructive lung disease [cited 2019 September 23]. Available from: https://goldcopd.org/
   Google Scholar
• Woodruff PG, van den Berge M, Boucher RC, et al. American Thoracic Society/National Heart, Lung, and Blood Institute asthma-chronic obstructive pulmonary disease overlap workshop report. Am J Respir Crit Care Med. 2017;196:375–381.
   PubMed Web of Science ®Google Scholar
• Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016;149:45–52.
   PubMed Web of Science ®Google Scholar
• van Boven JF, Roman-Rodriguez M, Palmer JF, et al. Comorbidome, pattern, and impact of asthma-COPD overlap syndrome in real life. Chest. 2016;149:1011–1020.
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48:664–673.
   PubMed Web of Science ®Google Scholar
• Lange P, Colak Y, Ingebrigtsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the copenhagen city heart study: a prospective population-based analysis. Lancet Respir Med. 2016;4:454–462.
   PubMed Web of Science ®Google Scholar
• Llanos JP, Ortega H, Germain G, et al. Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database. Int J Chron Obstruct Pulmon Dis. 2018;13:2859–2868.
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313:687–694.
   PubMed Web of Science ®Google Scholar
• Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253–1262.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;{5):CD009329.
   PubMedGoogle Scholar
• Maselli DJ, Hardin M, Christenson SA, et al. Clinical approach to the therapy of asthma-COPD overlap. Chest. 2019;155:168–177.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Chenoweth JA, Adams JY, et al. Muscarinic antagonists in early stage clinical development for the treatment of asthma. Expert Opin Investig Drugs. 2017;26:35–49.
   PubMed Web of Science ®Google Scholar
• Celli BR. Pharmacological therapy of COPD: reasons for optimism. Chest. 2018;154:1404–1415.
   PubMed Web of Science ®Google Scholar
• Alvarado-Gonzalez A, Arce I. Tiotropium bromide in chronic obstructive pulmonary disease and bronchial asthma. J Clin Med Res. 2015;7:831–839.
   PubMedGoogle Scholar
• Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102:50–56.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Bullick SW, Schivo M, et al. Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy. Drug Des Devel Ther. 2016;10:4047–4060.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Bowman WS, Harper RW, et al. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1251–1265.
   PubMed Web of Science ®Google Scholar
• Castiglia D, Battaglia S, Benfante A, et al. Pharmacological management of elderly patients with asthma-chronic obstructive pulmonary disease overlap syndrome: room for speculation? Drugs Aging. 2016;33:375–385.
   PubMed Web of Science ®Google Scholar
• Ding B, Small M. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey. Int J Chron Obstruct Pulmon Dis. 2017;12:1753–1763.
   PubMed Web of Science ®Google Scholar
• Muller V, Galffy G, Orosz M, et al. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data. Int J Chron Obstruct Pulmon Dis. 2016;11:93–101.
   PubMed Web of Science ®Google Scholar
• Chung LP, Paton JY. Two sides of the same coin? – Treatment of chronic asthma in children and adults. Front Pediatr. 2019;7:62.
   PubMed Web of Science ®Google Scholar
• O’Byrne P, Fabbri LM, Pavord ID, et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54:1900491.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641–647.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week phase III trial. Int J Chron Obstruct Pulmon Dis. 2012;7:43–55.
   PubMed Web of Science ®Google Scholar
• Reilly JJ. Stepping down therapy in COPD. N Engl J Med. 2014;371:1340–1341.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294.
   PubMed Web of Science ®Google Scholar
• Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. Respir Res. 2011;12:107.
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303.
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68–73.
   PubMed Web of Science ®Google Scholar
• Bujarski S, Parulekar AD, Sharafkhaneh A, et al. The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015;15:509.
   PubMed Web of Science ®Google Scholar
• Liesker JJ, Bathoorn E, Postma DS, et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011;105:1853–1860.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7:745–756.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Kostikas K, Fang J, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20:178.
   PubMed Web of Science ®Google Scholar
• Ishiura Y, Fujimura M, Shiba Y, et al. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome. Pulm Pharmacol Ther. 2015;35:28–33.
   PubMed Web of Science ®Google Scholar
• Lee SY, Park HY, Kim EK, et al. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2797–2803.
   PubMed Web of Science ®Google Scholar
• Lim HS, Choi SM, Lee J, et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol. 2014;113:652–657.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Murin S, Sutter ME, et al. The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials. Pragmat Obs Res. 2017;8:175–181.
   PubMed Web of Science ®Google Scholar
• Hines KL, Peebles RS Jr. Management of the asthma-COPD overlap syndrome (ACOS): a review of the evidence. Curr Allergy Asthma Rep. 2017;17:15.
   PubMed Web of Science ®Google Scholar
• Araujo D, Padrao E, Morais-Almeida M, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome – Literature review and contributions towards a Portuguese consensus. Rev Port Pneumol. 2017;23:90–99.
   PubMed Web of Science ®Google Scholar
• Lau EMT, Roche NA, Reddel HK. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap. Expert Rev Clin Immunol. 2017;13:449–455.
   PubMed Web of Science ®Google Scholar
• Kondo M, Tamaoki J. Therapeutic approaches of asthma and COPD overlap. Allergol Int. 2018;67:187–190.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438–446.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919–1929.
   PubMed Web of Science ®Google Scholar
• Bremner PR, Birk R, Brealey N, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19:19.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–1084.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394:1737–1749.
   PubMed Web of Science ®Google Scholar
• Ishiura Y, Fujimura M, Ohkura N, et al. Effect of triple therapy in patients with asthma-COPD overlap. Int J Clin Pharmacol Ther. 2019;57:384–392.
   PubMed Web of Science ®Google Scholar
• Ding B, Small M, Scheffel G, et al. Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care. Int J Chron Obstruct Pulmon Dis. 2018;13:927–936.
   PubMed Web of Science ®Google Scholar
• Walters JA, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(9):CD001288.
   Google Scholar
• Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(1):CD001288.
   PubMed Web of Science ®Google Scholar
• Miseviciene V, Liakaite G, Kevalas R. Short course of systemic corticosteroids in wheezy children: still an open question. Adv Respir Med. 2019;87:209–216.
   PubMed Web of Science ®Google Scholar
• Secombe P, Stewart P, Singh S, et al. Clinical management practices of life-threatening asthma: an audit of practices in intensive care. Crit Care Resusc. 2019;21:53–62.
   PubMed Web of Science ®Google Scholar
• Kirkland SW, Cross E, Campbell S, et al. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Cochrane Database Syst Rev. 2018;6:CD012629.
   PubMedGoogle Scholar
• Fernandes RM, Wingert A, Vandermeer B, et al. Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis. BMJ Open. 2019;9:e028511.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016;11:733–744.
   PubMed Web of Science ®Google Scholar
• Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53–67.
   PubMed Web of Science ®Google Scholar
• Pinner NA, Hamilton LA, Hughes A. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther. 2012;34:56–66.
   PubMed Web of Science ®Google Scholar
• Wan Y, Sun SX, Corman S, et al. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. Int J Chron Obstruct Pulmon Dis. 2015;10:2127–2136.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med. 2016;194:559–567.
   PubMed Web of Science ®Google Scholar
• Al-Sajee D, Yin X, Gauvreau GM. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma. Expert Opin Pharmacother. 2019;20:609–620.
   PubMed Web of Science ®Google Scholar
• Bardin P, Kanniess F, Gauvreau G, et al. Roflumilast for asthma: efficacy findings in mechanism of action studies. Pulm Pharmacol Ther. 2015;35(Suppl):S4–10.
   PubMedGoogle Scholar
• Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35(Suppl):S20–27.
   PubMedGoogle Scholar
• Zhang X, Chen Y, Fan L, et al. Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap. Drug Des Devel Ther. 2018;12:2371–2379.
   PubMed Web of Science ®Google Scholar
• Sanguinetti CM. N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med. 2015;11:8.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187–194.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017;14:552–563.
   PubMedGoogle Scholar
• Cramer CL, Patterson A, Alchakaki A, et al. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med. 2017;129:493–499.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3:331–350.
   PubMedGoogle Scholar
• Wang Q, Yu MF, Zhang WJ, et al. Azithromycin inhibits muscarinic 2 receptor-activated and voltage-activated Ca(2+) permeant ion channels and Ca(2+) sensitization, relaxing airway smooth muscle contraction. Clin Exp Pharmacol Physiol. 2019;45:329-336.
   Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698.
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–368.
   PubMed Web of Science ®Google Scholar
• Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013;(11):CD009764.
   PubMed Web of Science ®Google Scholar
• Yao GY, Ma YL, Zhang MQ, et al. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration. 2013;86:254–260.
   PubMed Web of Science ®Google Scholar
• Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013;107:637–648.
   PubMed Web of Science ®Google Scholar
• Johnston SL, Szigeti M, Cross M, et al. Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial. JAMA Intern Med. 2016;176:1630–1637.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:659–668.
   PubMed Web of Science ®Google Scholar
• Taylor SL, Leong LEX, Mobegi FM, et al. Long-term azithromycin reduces haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med. 2019;200:309–317.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188:901–906.
   PubMed Web of Science ®Google Scholar
• Devereux G, Cotton S, Fielding S, et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA. 2018;320:1548–1559.
   PubMed Web of Science ®Google Scholar
• Mahemuti G, Zhang H, Li J, et al. Efficacy and side effects of intravenous theophylline in acute asthma: a systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:99–120.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin K, Wang C, et al. Addition of theophylline or increasing the dose of inhaled corticosteroid in symptomatic asthma: a meta-analysis of randomized controlled trials. Yonsei Med J. 2011;52:268–275.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Hanania NA, Dini FL, et al. Impact of doxofylline compared to theophylline in asthma: a pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018;53:20–26.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201–2210.
   PubMed Web of Science ®Google Scholar
• Neukamm A, Hoiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med. 2015;278:59–67.
   PubMed Web of Science ®Google Scholar
• Carlson AA, Smith EA, Reid DJ. The stats are in: an update on statin use in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2277–2284.
   PubMed Web of Science ®Google Scholar
• Li WF, Huang YQ, Huang C, et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: an updated systematic review and meta-analysis of observational studies. Oncotarget. 2017;8:73000–73008.
   PubMedGoogle Scholar
• Zhang W, Zhang Y, Li CW, et al. Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest. 2017;152:1159–1168.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Oldham J, Wilson M, et al. Statin use and asthma control in patients with severe asthma. BMJ Open. 2013;3:e003314.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Elbadawi-Sidhu M. Innovations in asthma therapy: is there a role for inhaled statins? Expert Rev Respir Med. 2018;12:461–473.
   PubMed Web of Science ®Google Scholar
• Yeh JJ, Syue SH, Lin CL, et al. Statin use and vital organ failure in patients with asthma-chronic obstructive pulmonary disease overlap: a time-dependent population-based study. Front Pharmacol. 2019;10:889.
   PubMed Web of Science ®Google Scholar
• Del Giudice MM, Pezzulo A, Capristo C, et al. Leukotriene modifiers in the treatment of asthma in children. Ther Adv Respir Dis. 2009;3:245–251.
   PubMedGoogle Scholar
• Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast clinical research study group. Arch Intern Med. 1998;158:1213–1220.
   PubMed Web of Science ®Google Scholar
• Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
   PubMed Web of Science ®Google Scholar
• Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: systematic review and meta-analysis. Allergy Asthma Proc. 2014;35:278–287.
   PubMed Web of Science ®Google Scholar
• Virchow JC Jr., Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578–585.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Nathan RA, Kalberg C, et al. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. MedGenMed. 2001;3:3.
   PubMedGoogle Scholar
• Chen CF, Lv Y, Zhang HP, et al. Does zafirlukast reduce future risk of asthma exacerbations in adults? Systematic review and meta-analysis. Multidiscip Respir Med. 2014;9:30.
   PubMedGoogle Scholar
• Steinke JW, Culp JA. Leukotriene synthesis inhibitors versus antagonists: the pros and cons. Curr Allergy Asthma Rep. 2007;7:126–133.
   PubMed Web of Science ®Google Scholar
• Magazine R, Shahul HA, Chogtu B, et al. Comparison of oral montelukast with oral zileuton in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India. 2016;33:281–286.
   PubMed Web of Science ®Google Scholar
• Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157:1187–1194.
   PubMed Web of Science ®Google Scholar
• Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton clinical trial group. JAMA. 1996;275:931–936.
   PubMed Web of Science ®Google Scholar
• Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract. 2007;61:663–676.
   PubMed Web of Science ®Google Scholar
• Law SWY, Wong AYS, Anand S, et al. Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf. 2018;41:253–265.
   PubMed Web of Science ®Google Scholar
• Drakatos P, Lykouras D, Sampsonas F, et al. Targeting leukotrienes for the treatment of COPD? Inflamm Allergy Drug Targets. 2009;8:297–306.
   PubMedGoogle Scholar
• Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131:763–771.
   PubMed Web of Science ®Google Scholar
• Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD – a preliminary observation. Respir Med. 2004;98:134–138.
   PubMed Web of Science ®Google Scholar
• Gueli N, Verrusio W, Linguanti A, et al. Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): a preliminary report. Arch Gerontol Geriatr. 2011;52:e36–39.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Centanni S, Boveri B, et al. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration. 2001;68:452–459.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Albert RK, Bailey WC, et al. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD. 2011;8:21–29.
   PubMedGoogle Scholar
• Uzan GC, Borekci S, Doventas YE, et al. The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD. J Asthma. 2019 August 12;1–7. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kappen JH, Durham SR, Veen HI, et al. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Ther Adv Respir Dis. 2017;11:73–86.
   PubMed Web of Science ®Google Scholar
• Tosca MA, Licari A, Olcese R, et al. Immunotherapy and asthma in children. Front Pediatr. 2018;6:231.
   PubMed Web of Science ®Google Scholar
• Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72:1825–1848.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23:282–319.
   PubMedGoogle Scholar
• Gulsen A, Wallis S, Jappe U. Combination of immunotherapies for severe allergic asthma. J Asthma. 2019 September 5;1–4. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Singh D, Roche N, Halpin D, et al. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:541–549.
   PubMed Web of Science ®Google Scholar
• Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol. 2015;136:546–552.
   PubMed Web of Science ®Google Scholar
• Plaza V, Alvarez F, Calle M, et al. Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA). Arch Bronconeumol. 2017;53:443–449.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48:331–337.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136:531–545.
   PubMed Web of Science ®Google Scholar
• Cosio BG, Dacal D, Perez de Llano L. Asthma-COPD overlap: identification and optimal treatment. Ther Adv Respir Dis. 2018;12:1753466618805662.
   Web of Science ®Google Scholar
• Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18:747–754.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rogliani P, et al. Monoclonal antibodies for severe asthma: pharmacokinetic profiles. Respir Med. 2019;153:3–13.
   PubMed Web of Science ®Google Scholar
• Patel TR, Sur S. IgE and eosinophils as therapeutic targets in asthma. Curr Opin Allergy Clin Immunol. 2017;17:42–49.
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289.
   PubMed Web of Science ®Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68:158–166.
   PubMedGoogle Scholar
• Bagnasco D, Heffler E, Testino E, et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019;15:113–120.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16:186–200.
   PubMed Web of Science ®Google Scholar
• Hilvering B, Xue L, Pavord ID. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis. 2015;9:135–145.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Liu H, Pham TH, et al. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;20:14.
   PubMed Web of Science ®Google Scholar
• Saco TV, Pepper AN, Lockey RF. Benralizumab for the treatment of asthma. Expert Rev Clin Immunol. 2017;13:405–413.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143:190–200 e120.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Edris A, De Feyter S, Maes T, et al. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20:179.
   PubMed Web of Science ®Google Scholar
• Domingo C. Overlapping effects of new monoclonal antibodies for severe asthma. Drugs. 2017;77:1769–1787.
   PubMed Web of Science ®Google Scholar
• Santini G, Mores N, Malerba M, et al. Dupilumab for the treatment of asthma. Expert Opin Investig Drugs. 2017;26:357–366.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496.
   PubMed Web of Science ®Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bel EH, Ten Brinke A. New anti-eosinophil drugs for asthma and COPD: targeting the trait! Chest. 2017;152:1276–1282.
   PubMedGoogle Scholar
• Y Ousuf A, Ibrahim W, Greening NJ, et al. T2 biologics for chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2019;7:1405–1416.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Puxeddu E, et al. Emerging biological therapies for treating chronic obstructive pulmonary disease: a pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018;50:28–37.
   PubMed Web of Science ®Google Scholar
• Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045–1051.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017;49:1602486.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377:1613–1629.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Pavord ID, Paggiaro P, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease (COPD): a meta-analysis of METREX and METREO patient-reported outcomes, response to therapy and lung function. Am J Respir Crit Care Med. 2018;197:A4230.
   Google Scholar
• Fernandez Romero GA, Beros J, Criner G. Mepolizumab for the prevention of chronic obstructive pulmonary disease exacerbations. Expert Rev Respir Med. 2019;13:125–132.
   PubMed Web of Science ®Google Scholar
• Mkorombindo T, Dransfield MT. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:1779–1787.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA Jr., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2:891–901.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381:1023–1034.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2019 September 28. [Epub ahead of print]
   Google Scholar
• George L, Wright A, Mistry V, et al. Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab. Int J Chron Obstruct Pulmon Dis. 2019;14:1177–1185.
   PubMed Web of Science ®Google Scholar
• Fabbri LM. Benralizumab: for asthma, not yet for COPD. Lancet Respir Med. 2014;2:862–863.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Ora J, et al. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;31:15–27.
   PubMed Web of Science ®Google Scholar
• Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol. 2015;136:601–609.
   PubMed Web of Science ®Google Scholar
• Celli BR, Criner GJ. Using the peripheral blood eosinophil count to manage patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2019;16:301–303.
   PubMed Web of Science ®Google Scholar
• Nixon J, Newbold P, Mustelin T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57–77.
   PubMed Web of Science ®Google Scholar
• Gamo S, Iijima H, Seki Y, et al. Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease. Postepy Dermatol Alergol. 2019;36:239–241.
   PubMed Web of Science ®Google Scholar
• Gamo S, Iijima H, Seki Y, et al. Omalizumab rescued a asthma-COPD overlap syndrome patient from a status asthmatics under the ICU management. Arerugi. 2016;65:937–941.
   PubMedGoogle Scholar
• Tat TS, Cilli A. Omalizumab treatment in asthma-COPD overlap syndrome. J Asthma. 2016;53:1048–1050.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol Immunotoxicol. 2016;38:253–256.
   PubMed Web of Science ®Google Scholar
• Maltby S, Gibson PG, Powell H, et al. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017;151:78–89.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Chipps BE, Griffin NM, et al. Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143:1629–1633 e1622.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Milanese M, et al. Should omalizumab be used in severe asthma/COPD overlap? J Biol Regul Homeost Agents. 2018;32:755–761.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Gerhardsson de Verdier M, Agusti A, et al. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res. 2019;5:00036-2018.
   Google Scholar